Serum Tenascin-C: A novel biomarker for diagnosis and predicting prognosis of rheumatic carditis?

Journal of Tropical Pediatrics

Volumn 59, Issue 6, 2013, Pages 476-482

  Karatas, Zehra ^a   Baysal, Tamer ^a   Alp, Hayrullah ^a   Toker, Aysun ^a  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Acute rheumatic fever; Children; Chronic rheumatic heart disease; Tenascin C

Indexed keywords

ACETYLSALICYLIC ACID; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; PREDNISOLONE; TENASCIN;

AORTA VALVE REGURGITATION; ARTHRITIS; ARTICLE; CARDITIS; CHILD; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; MALE; PREDICTION; PRESCHOOL CHILD; PROGNOSIS; PROTEIN BLOOD LEVEL; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; RHEUMATIC PANCARDITIS; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ACUTE RHEUMATIC FEVER; CHILDREN; CHRONIC RHEUMATIC HEART DISEASE; TENASCIN-C;

ADOLESCENT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCARDITIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; ROC CURVE; TENASCIN;

EID: 84889015963     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmt058     Document Type: Article

References (26)

1. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010;30:17-23.
2. Tani LY. Rheumatic fever and rheumatic heart disease. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (eds). Moss and Adam's Heart Disease in Infants, Children and Adolescents. 7th edn. Philadelphia: Lippincott Williams and Wilkins, 2008, 1256-80.
3. Guidelines for the diagnosis of rheumatic fever. Jones criteria, 1992 update. Special Writting Group of the Comittee on Rheumatic Fever, Endocarditis, and Kawasaki disease of the counsil on cardiovascular disease in the young of the American Heart Association. JAMA 1992;268:2069-73. Erratum in: JAMA 1993;269:476.
4. Fan H, Liu W, Yan P. Pathological observation and immunohistochemistry study of Type I, III, IV collagen in mitral valve and cardiac interstitium of rheumatic disease. Zhonghua Yi Xue Za Zhi 1996;76:183-6.
5. Golledge J, Clancy P, Maguire J, et al. The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011;92:19-28.
6. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol 2011;31:115-45.
7. Jiang L, Wei XF, Yi DH, et al. Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells. Clin Exp Immunol 2009;155:216-23.
8. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
9. Rheumatic fever and rheumatic heart disease. World Health Organ Tech Rep Ser 2004;23:1-122.
10. Takamoto S, Kyo S, Adachi H, et al. Intraoperative color flow mapping by real-time two-dimensional Doppler echocardiography for evaluation of valvular and congenital heart disease and vascular disease. J Thorac Cardiovasc Surg 1985;90:802-12.
11. Wu YT, Chang AC, Chin AJ. Semiquantitative assessment of mitral regurgitation by Doppler color flow imaging in patients aged <20 years. Am J Cardiol 1993;71:727-32.
12. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005;167:71-80.
13. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004;19:517-25.
14. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, et al. The diagnostic utility of tenascin-C for evaluation of activity of human acute myocarditis. J Pathol 2005;205:460-7.
15. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2004;94:1468-70.
16. Sato A, Hiroe M, Akiyama D, et al. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Card Fail 2012;18:480-6.
17. Celik A, Gunebakmaz O, Baran O, et al. An investigation of tenascin-C levels in rheumatic mitral stenosis and their response to percutaneous mitral balloon valvuloplasty. Med Princ Pract 2013;22:29-34.
18. Satta J, Melkko J, Pöllänen R, et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 2002;39:96-101.
19. Guilherme L, Kalil J. Rheumatic fever: from innate to acquired immune response. Ann N Y Acad Sci 2007;1107:426-33.
20. Vollmer T, Hinse D, Kleesiek K, Dreier J. Interactions between endocarditis-derived Streptococcus gallolyticus subsp. gallolyticus isolates and human endothelial cells. BMC Microbiol 2010;10:78-89.
21. Sumioka T, Kitano A, Flanders KC, et al. Impaired cornea wound healing in a tenascin C-deficient mouse model. Lab Invest 2013;93:207-17.
22. Ikeshima-Kataoka H, Shen JS, Eto Y, et al. Alteration of inflammatory cytokine production in the injured central nervous system of tenascin-deficient mice. In Vivo 2008;22:409-13.
23. Guilherme L, Cury P, Demarchi LM, et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 2004;165:1583-91.
24. Terasaki F, Okamoto H, Onishi K, et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007;71:327-30.
25. Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol 2005;61:10-7.
26. Schöber W, Tran QB, Muringaseril M, et al. Impact of glafenine hydrochloride on human endothelial cells and human vascular smooth muscle cells: a substance reducing proliferation, migration and extracellular matrix synthesis. Cell Biol Int 2003;27:987-96.